IMRX
Immuneering Corporation·Healthcare
5.52
2.474%(−0.14)
Market ClosedLast Updated: — ET
52W L: $1.1052W H: $10.08
IMRX NEWS
globenewswire.com
4d ago
Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference
NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that Ben Zeskind, Chief Executive Officer, will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026 at 3:45 p.m. ET. The fireside chat will be webcast live and archived in the Investor Relations section of Immuneering's website at Events & Presentations | Immuneering Corporation.
defenseworld.net
Mar 23
Immuneering Corporation (NASDAQ:IMRX) Given Average Rating of “Moderate Buy” by Analysts
Shares of Immuneering Corporation (NASDAQ: IMRX - Get Free Report) have earned a consensus rating of "Moderate Buy" from the seven ratings firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, five have given a buy recommendation and one has given a strong buy recommendation to
globenewswire.com
Mar 17
Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival
Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability
defenseworld.net
Mar 12
Oxford BioMedica (OTCMKTS:OXBDF) and Immuneering (NASDAQ:IMRX) Financial Contrast
Oxford BioMedica (OTCMKTS:OXBDF - Get Free Report) and Immuneering (NASDAQ: IMRX - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings and valuation. Volatility and Risk Oxford BioMedica has a beta
247wallst.com
Mar 9
X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention
Analyst sentiment across three small-cap biotechs has turned notably positive, with fresh coverage initiations and maintained Buy-equivalent ratings from institutional research desks ahead of 2026 clinical catalysts.
globenewswire.com
Mar 6
Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
- 64% overall survival observed at 12 months in ongoing Phase 2a trial of atebimetinib + mGnP in first-line pancreatic cancer patients, well above the standard of care benchmark from GnP of 35% overall survival; On track for expanded pancreatic cancer cohort data readout in first half of 2026 - - On track to dose first patient in p ivotal Phase 3 MAPKeeper 301 trial of atebimetinib + mGnP in patients with first-line metastatic pancreatic cancer in mid-2026 - - Dosing in Phase 2 trial of atebimetinib + Libtayo® in patients with first-line RAS-mutant non-small cell lung cancer expected to begin in second half of 2026 - - Ended 2025 with $217 million in cash, cash equivalents and marketable securities with anticipated runway into 2029 - NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided business updates. “2025 was a transformative year for Immuneering.
